KR20120019968A - The method of extracting food component which have an antithrombotic effect from ficus carica linnoeus and the antithrombotic extract - Google Patents
The method of extracting food component which have an antithrombotic effect from ficus carica linnoeus and the antithrombotic extract Download PDFInfo
- Publication number
- KR20120019968A KR20120019968A KR1020100083618A KR20100083618A KR20120019968A KR 20120019968 A KR20120019968 A KR 20120019968A KR 1020100083618 A KR1020100083618 A KR 1020100083618A KR 20100083618 A KR20100083618 A KR 20100083618A KR 20120019968 A KR20120019968 A KR 20120019968A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- antithrombotic
- ethanol
- extracting
- extraction
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 31
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000002785 anti-thrombosis Effects 0.000 title claims abstract description 22
- 235000012041 food component Nutrition 0.000 title abstract description 6
- 239000005428 food component Substances 0.000 title abstract description 5
- 244000025361 Ficus carica Species 0.000 title 1
- 235000008730 Ficus carica Nutrition 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims description 19
- 230000002965 anti-thrombogenic effect Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 239000000306 component Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000000702 anti-platelet effect Effects 0.000 description 14
- 208000007536 Thrombosis Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 235000019784 crude fat Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
본 발명은 무화과로부터 항혈전 기능의 식품성분을 추출하는 방법 및 그 항혈전성 추출물에 관한 것으로, 보다 상세하게는 무화과로부터 콜라겐과 같은 응집유도체의 자극에 의해 활성화되어 응집반응을 일으키는 혈소판에 대하여 항응고작용을 나타내는 항혈전 기능의 추출물를 추출하는 방법 및 그 방법에 의하여 추출된 항혈전성 추출물에 관한 것이다.The present invention relates to a method for extracting anti-thrombotic food components from figs and an antithrombotic extract thereof, and more particularly, to anti-platelets that are activated by stimulation of agglutinant derivatives such as collagen from figs to cause agglutination. The present invention relates to a method for extracting an antithrombotic extract that exhibits a coagulation action and an antithrombogenic extract extracted by the method.
혈소판은 혈관 파손시에 혈액 응고인자들에 의한 응고 과정을 촉진시킴으로 혈관 파손 부위로 부터의 급격한 혈액의 손실을 방지하는 생체 방어기전이다. 그러나 폐쇄 혈관내에서의 혈소판 활성화에 의한 혈소판의 점착, 응집, 방출반응은 혈전형성을 초래하게 되고 이는 각종 혈전성 질환을 유발 시키게 됨으로 동맥경화증, 고혈압, 당뇨병 등의 성인병 발현에도 관여하게 되는 것이다. 따라서 이러한 혈소판응집 억제작용을 갖는 항혈소판 물질들은 혈전증상의 재발방지 및 다양한 혈전관련 질환의 치료 및 예방에 그 응용 가치가 크다고 하겠다.Platelets are a biological defense mechanism that prevents the rapid loss of blood from the site of blood vessel breakage by promoting the coagulation process by blood clotting factors during blood vessel breakage. However, adhesion, aggregation, and release of platelets by platelet activation in closed blood vessels result in thrombosis, which causes various thrombotic diseases and thus is involved in the expression of adult diseases such as atherosclerosis, hypertension, and diabetes. Therefore, these antiplatelet substances having platelet aggregation inhibitory action have great application value in preventing recurrence of thrombosis and treatment and prevention of various thrombosis related diseases.
혈전성 질환의 예방과 치료를 위하여 현재 사용되어지고 있는 약물로는 아스피린(aspirin)과 헤파린(heparin), 쿠마린(coumarin)등이 있으나 이들은 혈전에 관한 특이성이 없고 장기간 사용시에는 체내에서 출혈을 일으키는 등의 부작용이 있어 이에 따른 새로운 항혈소판제의 개발이 요구되어지고 있는 실정이다.Drugs currently being used for the prevention and treatment of thrombotic diseases include aspirin, heparin, and coumarin, but they are not specific for blood clots and cause bleeding in the body over long periods of time. There is a side effect of the development of a new antiplatelet agent is required accordingly.
이와 관련하여 연구자들은 다양한 천연물로부터의 항혈전 활성을 보고하고 있는데 무화과에서부터 분리한 에탄올 추출물로부터 이러한 활성이 보고되어지기도 하였다.(Anwarul HG et.al., Journal of Ethnopharmacology 119 (2008) 1-5)In this regard, researchers report antithrombotic activity from a variety of natural products, some of which have been reported from ethanol extracts isolated from figs (Anwarul HG et.al., Journal of Ethnopharmacology 119 (2008) 1-5).
그러나, 천연물로부터의 얻게되는 유효성분들은 추출 방법등에 따라 추출되는 성분들의 종류가 차이가 나게되고 기대되는 효과도 달라질 수 있다.However, the active ingredients obtained from natural products are different depending on the extraction method, the type of components to be extracted and the expected effect may also vary.
에 본 발명자들은 우수한 항혈전성 효과를 가지는 무화과의 추출방법에 대해 연구하였고 본 발명을 완성하였다. 본 발명은 무화과로부터 항혈전성 효과가 우수하면서도 부작용을 일으키지 않는 유효성분을 추출하는 방법 및 그 추출법에 의해 추출된 항혈전성 추출물을 제공하는 것을 목적으로 한다.The present inventors studied a method of extracting figs having an excellent antithrombogenic effect and completed the present invention. An object of the present invention is to provide a method for extracting an active ingredient having excellent antithrombogenic effect from figs and not causing side effects, and an antithrombogenic extract extracted by the extracting method.
상기 목적을 달성하기 위한 본 발병은 무화과를 절단하고 추출용매로 물을 사용하여 30℃이하에서 수용성 성분들을 추출하는 단계(P1), 추출용액을 원심분리하여 불용성 성분을 제거하는 단계(P2), 에탄올의 농도가 75%이상이 되도록 에탄올을 넣고 4℃에서 12시간 동안 정치시켜 에탄올 용해성 성분을 제거하는 단계(P3)를 포함하는 무화과로부터 항혈전성 성분을 추출하는 방법 및 항혈전효과가 우수한 무화과의 항혈전성 추출물에 관한 것이다.The present invention for achieving the above object is the step of cutting the fig and extracting the water-soluble components below 30 ℃ using water as the extraction solvent (P1), the step of centrifuging the extraction solution to remove the insoluble components (P2), Method of extracting anti-thrombotic components from figs including step (P3) of adding ethanol so that the concentration of ethanol is at least 75% and standing at 4 ° C. for 12 hours to remove ethanol-soluble components and figs having excellent antithrombotic effect It relates to an antithrombotic extract.
이하 본 발명을 상세히 설명하고자 한다.Hereinafter, the present invention will be described in detail.
건조시키거나 건조시키지 않은 무화과를 분쇄 혹은 절단한 뒤 추출용매를 사용하여 추출한다. 이때 추출용매로는 산, 염기 또는 물을 모두 사용할 수 있으나, 식품 원료로써의 안전성을 고려하여 물을 사용하여 추출하는 것이 바람직하겠다. 추출시 물의 온도는 30℃(최대 50℃)를 넘기지 않도록 하여 비교적 저온에서 추출하여야 한다.Fig dried or undried figs are crushed or cut and extracted using an extraction solvent. At this time, the acid, base or water can be used as the extraction solvent, but it is preferable to extract using water in consideration of safety as a food raw material. During extraction, the water temperature should be extracted at a relatively low temperature so that it does not exceed 30 ℃ (max 50 ℃).
추출이 완료되면 추출액은 원심분리기를 사용하여 침전시켜 상등액을 분리하고 이를 여과한다. 이후 여과된 추출액에 에탄올을 넣는다. 이때 에탄올의 최종농도가 75% 이상이 되도록 조절하여 넣고 12시간 동안 10℃에서 정치시킨 후 에탄올에 용해된 에탄올 용해성 성분을 분리하여 제거함으로 항혈전 효과가 우수한 무화과의 항혈전성 추출물을 제조 할 수 있다. 항혈전성 추출물은 그대로 사용하거나 필요에 따라 건조시켜 사용할 수 있다. 건조는 동결건조 등의 방법을 이용하며 건조 온도가 50℃가 넘지 않도록 하여야 한다. 상기 무화과의 항혈전성 추출물은 in vitro 실험에서 우수한 항혈전 효과를 나타낸다. 상기 추출물에 대하여 임피던스법(Impedence method)을 이용한 항혈소판 응집능을 측정한 결과 매우 우수한 항혈전효과를 나타내었다.After the extraction is completed, the extract is precipitated using a centrifuge to separate the supernatant and filter it. Then ethanol is added to the filtered extract. At this time, the final concentration of ethanol is adjusted to be 75% or more, and the mixture is allowed to stand at 12 ° C. for 12 hours, and then the ethanol soluble components dissolved in ethanol are separated and removed to prepare an antithrombotic extract of figs having excellent antithrombotic effect. have. The antithrombotic extract can be used as it is or dried as necessary. Drying should be done by lyophilization method and drying temperature should not exceed 50 ℃. The antithrombotic extract of figs shows excellent antithrombotic effect in in vitro experiments. As a result of measuring the antiplatelet aggregation ability using the impedance method (Impedence method) for the extract showed a very good antithrombotic effect.
본 발명의 추출 방법에 의해 무화과로부터 항혈소판 응집능이 탁월한 물질을 추출할 수 있다. 그 추출물은 콜라겐(collagen)과 같은 응집유도체의 자극에 의해 응집반응을 일으키는 혈소판의 활성화를 방지함으로 이에따른 혈액응고체계의 가속화를 막아 궁극적으로 혈전의 생성을 억제할 수 있는 것이다. 따라서 이는 뇌출혈, 심근경색, 동맥경화 등의 심혈관계 질환의 예방에 이용 될 수 있으며, 또한 무화과는 식품임으로 부작용이 없다는 장점이 있다.By the extraction method of the present invention, it is possible to extract substances excellent in antiplatelet aggregation ability from figs. The extract prevents the activation of platelets causing the aggregation reaction by stimulation of agglutinating derivatives such as collagen, thereby preventing the acceleration of the blood coagulation system and ultimately inhibiting the generation of blood clots. Therefore, it can be used for the prevention of cardiovascular diseases such as cerebral hemorrhage, myocardial infarction, arteriosclerosis, etc. Also, since figs are foods, there are no side effects.
도 1. 저온 추출을 특징으로하는 무화과로부터 항혈전성 추출물 제조 공정 모식도Figure 1. Schematic diagram of a process for producing antithrombogenic extract from figs characterized by low temperature extraction
이하 본발명을 실시예를 통해 보다 상세하게 설명하고자 한다.Hereinafter, the present invention will be described in more detail with reference to Examples.
실시예 1)Example 1
추출시 용매의 추출온도에 따른 추출물의 항응고활성을 비교하기 위하여 무화과를 절단하고 이를 각각 10℃, 30℃, 50℃, 70℃, 100℃의 온도로 추출한 후 여과하고 에탄올을 첨가하여 에탄올 용해성 물질을 제거한 뒤 임피던스법을 이용한 항혈소판 응집능을 측정하였다.In order to compare the anticoagulant activity of the extract according to the extraction temperature of the solvent during the extraction, the figs were cut and extracted at temperatures of 10 ° C., 30 ° C., 50 ° C., 70 ° C. and 100 ° C., respectively, filtered and ethanol was dissolved by adding ethanol. After removing the material, the antiplatelet aggregation ability was measured by the impedance method.
임피던스법은 혈액내로 전류를 통과시켜 혈소판 응집에 따른 전기적 저항의 변화를 측정하는 방법으로 전혈(Whole blood)에서의 측정이 가능한 방법이다.Impedance method is a method of measuring the change in electrical resistance according to platelet aggregation by passing a current through the blood is a method that can be measured in whole blood.
실험을 위하여 6주령의 SD(Sprague-Dewley)rat으로부터 채혈하여 0.38% 구연산나트륨(sodium citrate)을 혈액에 대하여 1:9(v/v)의 비율이 되도록 한 전혈(Whole blood)을 사용하였다.Whole blood was used for the experiment to collect 0.38% sodium citrate at a ratio of 1: 9 (v / v) to blood by collecting blood from 6 week old Sprague-Dewley rats.
상기의 추출방법에 따른 무화과의 온도별 추출물을 5mg/mL의 농도로 희석하여 각각을 전혈에 처리한 후 콜라겐에 의한 응집유도 후 각각의 저항값을 측정하고 이를 아래 수학식에 따라 항혈소판활성을 계산하였다. 계산한 항혈소판활성은 표1에 나타내었다.After diluting the extract by the temperature of the fig according to the above extraction method to a concentration of 5mg / mL, each was treated with whole blood and measured the resistance values after the coagulation induction by collagen. Calculated. The calculated antiplatelet activity is shown in Table 1.
수학식 항혈소판활성(%) =Equation (%) = antiplatelet activity
표1Table 1
상기 표1의 결과에서 추출온도가 증가할수록 항혈소판활성이 감소함을 알 수 있었다.In the results of Table 1, the antiplatelet activity was decreased as the extraction temperature was increased.
실시예 2)Example 2
본 발명의 추출 방법에 의해 제조된 무화과 추출물에 대한 항혈소판능을 기존에 보고된바 있는 무화과 에탄올 추출물과 활성을 비교함으로 본 발명에 의한 무화과 추출물의 우수성을 확인하였다. 무화과 에탄올 추출물의 제조는 기존 보고자료에 기술한 방법을 충실히 따라 제조하였다. 항혈소판능의 활성은 실시예 1에서 기술한 실험법을 따라 측정하였다.The antiplatelet activity of the fig extract prepared by the extraction method of the present invention was confirmed by comparing the activity of the fig ethanol extract with the previously reported fig ethanol extract of the present invention. The preparation of the fig ethanol extract was made faithfully following the method described in the previous report. The activity of antiplatelet activity was measured according to the experimental method described in Example 1.
표2Table 2
상기표2의 결과에서 본 발병 무화과 추출물에서 뛰어난 항혈소판활성을 또한 확인 할 수 있었다. 다만 항혈소판 활성이 있다고 보고된 기존보고 무화과 추출물의 경우, 항혈소판활성을 나타내지 않았다. 이는 본 실시예에서 사용된 실험법의 차이에 기인된 것으로 판단된다. 기존 보고에서는 항혈소판 활성 확인을 위하여 PRP(Platelet Rich Plasma)를 사용하고 혈소판 응집 inducer로써 ADP와 Adrenaline을 사용한 반면 본 실시예에서는 전혈내 혈소판만을 이용하였고 혈소판 응집 inducer는 collagen을 사용하였다.From the results of Table 2, it was also confirmed excellent antiplatelet activity in the pathogenic fig extract. However, in the case of the previously reported fig extract reported to have antiplatelet activity, it did not show antiplatelet activity. This is believed to be due to the difference in the experimental method used in this example. In the previous report, platelet rich plasma (PRP) was used to identify antiplatelet activity and ADP and Adrenaline were used as platelet aggregation inducers. In this example, only whole blood platelets were used and platelet aggregation inducer was used as collagen.
실시예 3)Example 3
항혈전 활성을 나타내는 무화과 추출물의 성분을 확인하기위하여 추출물 내 영양성분과 총다당체함량 분석하였다. 영양성분 중 지방은 Soxhlet extract 법을, 단백질은 kjedahl method를 이용하였고 수분과 회분은 상압가열건조법으로 측정하였다. 탄수화물의 함량은 이들의 값으로부터 다음의 계산식에 적용하여 함량을 확인하였으며 총다당체의 함량은 페놀과 황산을 이용한 발색법으로 측정하였다.To determine the components of the fig extract showing antithrombotic activity, the nutritional components and total polysaccharide content of the extract were analyzed. Fat was measured by Soxhlet extract method, protein was kjedahl method, and moisture and ash were measured by atmospheric heating. Carbohydrate content was determined from these values by applying the following formula and the total polysaccharide content was measured by color development using phenol and sulfuric acid.
탄수화물 함량 계산식 = 100-(조지방+조단백질+수분+회분)Carbohydrate Content Formula = 100- (Crude Fat + Crude Protein + Moisture + Ash)
표3Table 3
표4Table 4
분석결과, 상기표3에서 본발명 무화과 추출물의 영양성분은 탄수화물 67.51%, 조단백질 12.52%, 조지방 0.11% 및 탄수화물 중 총다당체의 함량이 10.35%로 나타난 반면, 기존 보고 무화과 에탄올 추출물은 탄수화물 65.52%, 조단백질 6.57%, 조지방 0.73% 및 탄수화물 중 총다당체의 함량이 0.94%으로(표 4) 두 추출물간 성분조성에 큰 차이를 확인 할 수 있었고 이는 두 추출물이 상이한 물질임을 나타낸다.As a result of the analysis, the nutrient composition of the present invention fig extract is carbohydrate 67.51%, crude protein 12.52%, crude fat 0.11% and carbohydrate content of 10.35%, whereas the previously reported fig ethanol extract carbohydrate 65.52%, 6.57% of crude protein, 0.73% of crude fat and 0.94% of total polysaccharide in carbohydrates (Table 4) showed a big difference in the composition of the two extracts, indicating that the two extracts are different substances.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100083618A KR101144433B1 (en) | 2010-08-27 | 2010-08-27 | The method of extracting food component which have an antithrombotic effect from Ficus Carica Linnoeus and the antithrombotic extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100083618A KR101144433B1 (en) | 2010-08-27 | 2010-08-27 | The method of extracting food component which have an antithrombotic effect from Ficus Carica Linnoeus and the antithrombotic extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120019968A true KR20120019968A (en) | 2012-03-07 |
KR101144433B1 KR101144433B1 (en) | 2012-05-15 |
Family
ID=46128753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100083618A KR101144433B1 (en) | 2010-08-27 | 2010-08-27 | The method of extracting food component which have an antithrombotic effect from Ficus Carica Linnoeus and the antithrombotic extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101144433B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103704796A (en) * | 2014-01-14 | 2014-04-09 | 广西南宁桂景大酒店有限责任公司 | Spiral seaweed and maca soup and production method thereof |
CN105211847A (en) * | 2015-10-23 | 2016-01-06 | 苏春培 | The preparation method of Hericium erinaceus conidia powder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100685110B1 (en) * | 1999-04-24 | 2007-02-22 | (유)키토산메디신테크 | The manufacturing process of Can drink beverage by use of activated Figue material |
KR100966838B1 (en) * | 2007-12-28 | 2010-06-29 | 재단법인 대구테크노파크 | A beverage using fig and a preparation method thereof |
-
2010
- 2010-08-27 KR KR1020100083618A patent/KR101144433B1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103704796A (en) * | 2014-01-14 | 2014-04-09 | 广西南宁桂景大酒店有限责任公司 | Spiral seaweed and maca soup and production method thereof |
CN105211847A (en) * | 2015-10-23 | 2016-01-06 | 苏春培 | The preparation method of Hericium erinaceus conidia powder |
Also Published As
Publication number | Publication date |
---|---|
KR101144433B1 (en) | 2012-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3018219C (en) | Corn protein concentrate and methods of manufacturing same | |
JP2015515493A5 (en) | ||
JP7011060B2 (en) | Fibrous structure derived from potato protein and foodstuffs containing it | |
Sabbione et al. | Antithrombotic effects of Amaranthus hypochondriacus proteins in rats | |
KR101144433B1 (en) | The method of extracting food component which have an antithrombotic effect from Ficus Carica Linnoeus and the antithrombotic extract | |
KR101645855B1 (en) | Pharmaceutical composition comprising the extract of lepiduium meyenii hypocotyl as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
CN104558115A (en) | Antioxidant polypeptide with Raja porosa meat protein as well as preparation method and application of antioxidant polypeptide | |
KR101378527B1 (en) | Composition comprising the extract of Cedrela sonensis A. Juss for prevention or control of thrombosis | |
Ryu et al. | Beneficial effect of persimmon leaves and bioactive compounds on thrombosis | |
KR100704003B1 (en) | A compound comprising 2?-hydroxy-oleanolic acid for prevention and control of thrombosis | |
KR101361148B1 (en) | Pharmaceutical and Food composition comprising juice of white radish Raphanus sativus L. for prevention or control of thrombosis | |
KR102084503B1 (en) | Pharmaceutical composition comprising the zingiber officinale leaf extracts as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
KR101338190B1 (en) | Pharmaceutical and Food composition comprising the antioxidant juice of bordeaux radish Raphanus sativus L. for prevention or control of thrombosis | |
KR102117896B1 (en) | Composition comprising Extract of Crataegus pinnatifida Bunge for Antithrombosis | |
RU2421024C1 (en) | Method for complex processing of dandelion roots | |
KR101645878B1 (en) | Pharmaceutical composition comprising the organic solvent fractions of platycodon grandiflorum as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
JP2006028074A (en) | Blood platelet coagulation inhibitory composition | |
KR100345983B1 (en) | Syzygium Aromaticum Extract Having Anti-coagulation Effect and its Refining Method | |
KR20150104868A (en) | Pharmaceutical composition for prevention or treatment of thrombosis comprising the seed extract of cornus officinalis | |
KR20140109099A (en) | A pharmaceutical composition comprising the hexane fraction of gardenia jasminoides extract as an effective component for anti-platelet aggregation and a health functional food comprising the same | |
KR102216218B1 (en) | Pharmaceutical composition comprising ethanol extracts of seedpod of nelumbo nucifera as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
KR101125718B1 (en) | Food additive composition comprising of cherry extracts against blood clots by inhibiting thrombin activity | |
US2284566A (en) | Products capable of preventing the coagulation of blood and a method of making the same | |
KR20190066491A (en) | Pharmaceutical composition comprising the extracts from the flesh and seed of passion fruit as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
KR102120490B1 (en) | Pharmaceutical composition for prevention or treatment of thrombosis comprising the ethylacetate fraction of shiitake mushroom extract as an effective component and health functional food comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160411 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170425 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180410 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190416 Year of fee payment: 8 |